At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 550 enrolled
Drug / intervention
Meropenem-Vaborbactam +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis
In Brief
A Phase 3 clinical trial evaluating Meropenem-Vaborbactam, Piperacillin-Tazobactam, and 2 other interventions for Urinary Tract Infection Complicated and Acute Pyelonephritis. Completed, enrolled 550 participants across 77 sites in 17 countries.
Detailed Summary
Meropenem-vaborbactam is being compared to piperacillin-tazobactam in the treatment of adults with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelarus, Brazil, Bulgaria, Czechia, Greece, Hungary, Italy, Peru, Poland, Romania, Slovakia, Slovenia, South Korea, Spain, Taiwan, Ukraine, United States
CollaboratorsDepartment of Health and Human Services
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartNov 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedJun 18, 2014
Enrollment StartNov 20, 2014
Primary CompletionApr 28, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.0 years ago
Interventions
Meropenem-Vaborbactamdrug
Meropenem-vaborbactam
Piperacillin-Tazobactamdrug
Piperacillin-tazobactam
Levofloxacindrug
Levofloxacin
Salinedrug
Saline